{
  "abstract": "Adults and children aged 10 years or older with polyendocrine metabolic ovarian syndrome (PMOS) should be offered an annual review to manage their symptoms, check medications, and assess their long term risk of health conditions such as cardiovascular disease and diabetes.1",
  "authors": [
    {
      "affiliations": [
        "The BMJ"
      ],
      "name": "Elisabeth Mahase"
    }
  ],
  "title": "PMOS: NICE updates assessment and review recommendations in new guidance after condition’s name change",
  "uid": "370b75e1-d919-5881-84fe-a896b27ad604"
}